Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | WHR1 | P49842 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22428683 | 0.87 | GRM4 (0.39) | GRM4TRPA1BCDIN3DMBOAT4JAK2 | |
| SCHEMBL22428805 | 0.80 | GRM4 (0.35) | GRM4TRPA1JAK2 | |
| SCHEMBL28926930 | 0.76 | MBOAT4 (0.41) | GRM4TRPA1BCDIN3DMBOAT4JAK2 | |
| SCHEMBL30873882 | 0.76 | MBOAT4 (0.41) | GRM4TRPA1BCDIN3DMBOAT4JAK2 | |
| SCHEMBL22428680 | 0.71 | IDH1 (0.39) | GRM4MBOAT4JAK2IDH1CYP1A2 | |
| SCHEMBL22428674 | 0.67 | MEN1 (0.41) | WHR1 | |
| SCHEMBL22411339 | 0.67 | MBOAT4 (0.37) | GRM4TRPA1BCDIN3DMBOAT4JAK2 | |
| SCHEMBL26618136 | 0.63 | GRM4 (0.39) | GRM4TRPA1MAPK1IDH1 | |
| SCHEMBL30873917 | 0.63 | TRPA1 (0.39) | GRM4TRPA1BCDIN3DMBOAT4JAK2 | |
| SCHEMBL28648458 | 0.63 | TRPA1 (0.39) | GRM4TRPA1BCDIN3DMBOAT4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020185738-A1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | GPX4, GPX1, AIFM2 | GRM4 2492/4885TRPA1 4654/4885BCDIN3D 1439/4885 |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | AIFM2, FECH, SLC40A1 | GRM4 2245/4885TRPA1 1513/4885BCDIN3D 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.